These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

108 related articles for article (PubMed ID: 18676156)

  • 21. The evolving role of cetuximab in non-small cell lung cancer.
    Lilenbaum RC
    Clin Cancer Res; 2006 Jul; 12(14 Pt 2):4432s-4435s. PubMed ID: 16857823
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Cutaneous squamous cell carcinoma responding serially to single-agent cetuximab.
    Suen JK; Bressler L; Shord SS; Warso M; Villano JL
    Anticancer Drugs; 2007 Aug; 18(7):827-9. PubMed ID: 17581306
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Cetuximab and cancers of the head and neck: tapping the circadian rhythm.
    Shukla P; Gupta D; Munshi A; Agarwal JP
    Med Hypotheses; 2011 Sep; 77(3):336-8. PubMed ID: 21616603
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Avelumab and cetuximab as a therapeutic combination: An overview of scientific rationale and current clinical trials in cancer.
    Bourhis J; Stein A; Paul de Boer J; Van Den Eynde M; Gold KA; Stintzing S; Becker JC; Moran M; Schroeder A; Pennock G; Salmio S; Esser R; Ciardiello F
    Cancer Treat Rev; 2021 Jun; 97():102172. PubMed ID: 33989949
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Aseptic meningitis: a rare side effect of cetuximab therapy.
    Emani MK; Zaiden RA
    J Oncol Pharm Pract; 2013 Jun; 19(2):178-80. PubMed ID: 22623275
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Complete sustained regression of extensive psoriasis with cetuximab combination chemotherapy.
    Trivin F; Boucher E; Raoul JL
    Acta Oncol; 2004; 43(6):592-3. PubMed ID: 15370619
    [No Abstract]   [Full Text] [Related]  

  • 27. Characterization of 7A7, an anti-mouse EGFR monoclonal antibody proposed to be the mouse equivalent of cetuximab.
    He X; Cruz JL; Joseph S; Pett N; Chew HY; Tuong ZK; Okano S; Kelly G; Veitch M; Simpson F; Wells JW
    Oncotarget; 2018 Feb; 9(15):12250-12260. PubMed ID: 29552307
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Development and clinical indications of cetuximab.
    Labianca R; La Verde N; Garassino MC
    Int J Biol Markers; 2007 S4 - Jan-Mar; 22(4):40-46. PubMed ID: 28207113
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Review of cetuximab in the treatment of squamous cell carcinoma of the head and neck.
    Merlano M; Occelli M
    Ther Clin Risk Manag; 2007 Oct; 3(5):871-6. PubMed ID: 18473010
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Hypomagnesaemia in oncologic patients: to treat or not to treat?
    Wolf FI; Trapani V; Cittadini A; Maier JA
    Magnes Res; 2009 Mar; 22(1):5-9. PubMed ID: 19441269
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Concomitant cetuximab and radiation therapy: A possible promising strategy for locally advanced inoperable non-melanoma skin carcinomas.
    Della Vittoria Scarpati G; Perri F; Pisconti S; Costa G; Ricciardiello F; Del Prete S; Napolitano A; Carraturo M; Mazzone S; Addeo R
    Mol Clin Oncol; 2016 Apr; 4(4):467-471. PubMed ID: 27073643
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The development, optimization and validation of an ELISA bioanalytical method for the determination of Cetuximab in human serum.
    Hantash J; Smidt M; Bowsher RR
    Anal Methods; 2009 Nov; 1(2):144-148. PubMed ID: 32938155
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Treatment of advanced head and neck cancer with cetuximab.
    Merlano M; Garrone O
    Int J Biol Markers; 2007 S4 - Jan-Mar; 22(4):71-76. PubMed ID: 28207117
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Recurrent squamous cell carcinoma of the skin treated successfully with single agent cetuximab therapy.
    Seber S; Gonultas A; Ozturk O; Yetisyigit T
    Onco Targets Ther; 2016; 9():945-8. PubMed ID: 26955287
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Evaluating the efficacy of the anticancer drug cetuximab by atomic force microscopy.
    Zhang Q; Shi Y; Xu H; Zhou L; Gao J; Jiang J; Cai M; Shan Y
    RSC Adv; 2018 Jun; 8(39):21793-21797. PubMed ID: 35541738
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Cetuximab: from bench to bedside.
    Vincenzi B; Zoccoli A; Pantano F; Venditti O; Galluzzo S
    Curr Cancer Drug Targets; 2010 Feb; 10(1):80-95. PubMed ID: 20088790
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Interleukin-12 in multimodal tumor therapies for induction of anti-tumor immunity.
    Xu Y; Sun X; Tong Y
    Discov Oncol; 2024 May; 15(1):170. PubMed ID: 38753073
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Phenotypic switching as a non-genetic mechanism of resistance predicts antibody therapy regimens.
    Zhou J; Liu C; Tang Y; Li Z; Cao Y
    iScience; 2024 Apr; 27(4):109450. PubMed ID: 38544569
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Nanostructures for site-specific delivery of oxaliplatin cancer therapy: Versatile nanoplatforms in synergistic cancer therapy.
    Bagheri M; Zandieh MA; Daryab M; Samaei SS; Gholami S; Rahmanian P; Dezfulian S; Eary M; Rezaee A; Rajabi R; Khorrami R; Salimimoghadam S; Hu P; Rashidi M; Ardakan AK; Ertas YN; Hushmandi K
    Transl Oncol; 2024 Jan; 39():101838. PubMed ID: 38016356
    [TBL] [Abstract][Full Text] [Related]  

  • 40.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.